Serum Receptor Activator of Nuclear Factor-κβ Ligand and Osteoprotegerin Levels and Ratio in Correlation with Bone Mineral Density

Authors

  • Fauqa Arinil Aulia Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya
  • Sri Lestari Utami Department of Biomedicine, Faculty of Medicine, Wijaya Kusuma University, Surabaya
  • Leonita Anniwati Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya
  • Sony Wibisono Mudjanarko Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya
  • Ferdy Royland Marpaung Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

DOI:

https://doi.org/10.24293/ijcpml.v27i1.1627

Keywords:

RANKL, osteoprotegerin, bone mineral density, osteoporosis, post-menopausal females

Abstract

Osteoporosis is a disorder represented by manifestations of low bone mass, decreased bone tissue, and disrupted bone microarchitecture. The diagnosis of osteoporosis so far has been based on fracture manifestations after minimal trauma or by detecting low Bone Mineral Density (BMD). Measurement of Receptor Activator of Nuclear Factor-κβ Ligand (RANKL) and Osteoprotegerin (OPG) levels has opened the discourse of a more specific assessment of osteoblast and osteoclast regulation. The RANKL/OPG ratio can represent resorption and bone formation more significantly when correlated with BMD features. This study aimed to analyze the correlation between serum RANKL and OPG levels and ratio with BMD. A total of 58 post-menopausal females from 13 elderly in Integrated Community Health Care Surabaya and Sidoarjo were enrolled. Data were collected by recording age, onset of menarche, onset of menopause, and Body Mass Index (BMI). Serum RANKL and OPG levels were evaluated using sandwich ELISA from Elabscience®. The RANKL/OPG ratio was obtained from the ratio between measured RANKL and OPG levels in serum. The proximal femur and lumbar spine BMDs were measured using Hologic® Discoveryâ„¢ QDRâ„¢ Dual-Energy X-ray Absorptiometry (DEXA). Pearson's correlation test in this study showed no significant correlation between BMD and RANKL levels (lumbar: p=0.203; hip: p=0.283). The insignificant result was also shown in the correlation between BMD and OPG levels (lumbar: p=0.412; hip: p=0.617). A significant result between lumbar BMD and RANKL/OPG ratio was only found in the osteopenia subjects (p=0.001). The RANKL/OPG ratio had a significant correlation only with osteopenia-BMD in post-menopausal females. Therefore, it could be used as supporting data in osteoporosis screening.

Downloads

Download data is not yet available.

Author Biographies

Fauqa Arinil Aulia, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Sri Lestari Utami, Department of Biomedicine, Faculty of Medicine, Wijaya Kusuma University, Surabaya

Department of Biomedicine, Faculty of Medicine, Wijaya Kusuma University, Surabaya

Leonita Anniwati, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Sony Wibisono Mudjanarko, Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Ferdy Royland Marpaung, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya

References

Sözen, T, í–zı şı k, L, BaÅŸaran, NC. An overview and management of osteoporosis. European Journal of Rheumatology, 2017; 4: 46-56.

Mithal A, Kaur P. Osteoporosis in Asia: A call to action. Curr Osteoporos Rep, 2012; 10: 245–7.

Kementerian Kesehatan Republik Indonesia. Data & kondisi penyakit osteoporosis di Indonesia. Jakarta, Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia, 2015, 2-6.

Sheu A, Diamond T. Bone mineral density: Testing for osteoporosis. Aust Prescr, 2016; 39: 35-91.

G a r n e r o P . B i o m a r k e r s f o r o s t e o p o r o s i s management–utility in diagnosis, fracture risk prediction, and therapy monitoring. Journal of Endocrine Disorders, Mol Diag Ther, 2008; 12(3):

-70.

Sennels HP, Jacobsen S, Jensen T, Hansen MS, Ostergaard M, et al. Biological variation and reference

intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. Scand J Clin Lab Invest, 2007; 67: 821–35.

Khosla S. Mini review: The OPG/RANKL/RANK system. Endocrinol, 2001; 142: 5050–55.

Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research & Therapy, 2007;

(S1): 1689-1697.

World Health Organization. Body mass index–BMI. h t t p : / / w w w . e u r o . w h o . i n t / e n / h e a l t h - t o p i c s /disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi (Updated on Nov, 2019).

World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. Brussel-Belgium, Summary Meeting Report, 2004; 2.

Elabscience®. Manual book-human sRANKL (soluble receptor activator of nuclear factor-kB ligand) ELISA Kit, 7 Ed., USA, Elabscience®, 2017; 1-11.

E l a b s c i e n c e ® . M a n u a l b o o k - h u m a n O P G t h (osteoprotegerin) ELISA Kit, 7 Ed., USA,

Elabscience®, 2017; 1-11.

Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G. Circulating levels of receptor activator of nuclear factor-kB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. European Journal of Endocrinology, 2004; 150: 305–11.

Widodo H, Anisa FN, Lianti D. Relationship of physical activity, diet, and age menarche with age menopause at elderly Posyandu working area Puskesmas Pekauman Banjarmasin. Advances in Health Science Research, 2017; 6: 566–74.

Ahuja M. Age of menopause and determinants of menopause age: A PAN India survey by IMS. J Mid-life Health, 2016; 7: 126–31.

Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin N Am, 2011;

: 425–40.

Lambrinoudaki I, Tsouvalas E, Vakaki M, Kaparos G, Stamatelopoulos K, et al. Osteoprotegerin, soluble receptor activator of nuclear factor-KB ligand, and subclinical atherosclerosis in children and adolescents with type 1 diabetes mellitus. International Journal of Endocrinology, 2013; 2013: 1-8

Holecki M, Zahorska-Markiewicz B, Janowska J, Nieszporek T. The influence of weight loss on

serum osteoprotegerin concentration in obese perimenopausal women. Obesity, 2007; 15(8): 1925–9.

Dimitri P, Wales JK, Bishop N. Adipokines, bonederived factors and bone turnover in obese children; Evidence for altered fat-bone signaling resulting in reduced bone mass. Bone, 2011; 48(2): 189–96.

actor-KB ligand, and subclinical atherosclerosis in children and adolescents with type 1 diabetes mellitus. International Journal of Endocrinology, 2013; 2013: 1-8.

Hsu YH, Venners SA, Terwedow HA, Feng Y, Niu T, Li Z, et al. Relation of body composition, fat

mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and

women. Am J Clin Nutr, 2006; 83: 146–54.

Ahmad EA, Abbas M, Amir R, Mohammad S. The relationship between body weight, Body Mass

Index (BMI) and Bone Mineral Density (BMD) of the lumbar spine and femoral neck in professional cyclist of Iran and tour de France. Iranian Journal of Health and Physical Activity, 2012; 4: 67–71.

Iqbal SI, Morch LS, Rosenzweig M, Dela F. The outcome of bone mineral density measurements

on patients referred from general practise. Journal of Clinical Densitometry, 2005; 8: 178-82.

Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, et al. Relationships among serum receptor

of nuclear factor-JB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in post-menopausal women: osteoimmunity versus osteoinflammatory. The Journal of the North American Menopause Society, 2009; 16(5): 950–5.

Kim SJ, Yang WG, Cho E, Park E. Relationship between weight, body mass index, and bone

mineral density of lumbar spine in women. J Bone Metab, 2012; 19: 95–102.

F a h r l e i t n e r - P a m m e r A , D o b n i g H, Piswanger-Soelkner, C. Osteoprotegerin serum

levels in women: correlation with age, bone mass, bone turnover, and fracture status. Wien

Klin Wochenschr, 2003; 115: 291–7.

Mendez JP, Mejia DR, Pedraza J, Vazquez RMC, Soriano R, et al. Bone mineral density in post-menopausal Mexican-Mestizo women with normal body mass index, overweight, or obesity. Menopause, 2013; 20: 568–72.

Bolotin HH. DXA in-vivo BMD methodology: An erroneous and misleading research and clinical

gauge of bone mineral status, bone fragility, and bone remodeling. Bone, 2007; 41: 138–54.

Brown SE. Osteoporosis: Snap, crackle, and pop some pills. Northeast Florida Med, 2006; 57: 14-20.

Shanthi JC, McLeod W, Kennedy L, McLeod K. Osteoporosis health beliefs among younger and

older men and women. Health Educ Behav, 2008; 35(5): 721–33.

Pietschmann P, Rauner M, Sipos W, Schindl KK. Osteoporosis: An age-related and gender-specific disease a mini-review. Gerontology, 2009; 55: 3-12.

Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int, 2005; 76: 1–6.

Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation, and aging. Immun Ageing, 2005; 2: 14.

Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas, 2008; 60: 65–9.

Downloads

Submitted

2020-02-04

Accepted

2020-07-07

Published

2020-12-07

How to Cite

[1]
Aulia, F.A., Utami, S.L., Anniwati, L., Mudjanarko, S.W. and Marpaung, F.R. 2020. Serum Receptor Activator of Nuclear Factor-κβ Ligand and Osteoprotegerin Levels and Ratio in Correlation with Bone Mineral Density. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 27, 1 (Dec. 2020), 76–82. DOI:https://doi.org/10.24293/ijcpml.v27i1.1627.

Issue

Section

Articles